• Nutriband's Innovative Patent Breaks New Ground in Transdermal Medications
  • Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
  • Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
  • Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
  • Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador
  • Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
  • Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission
  • Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.